NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01393600 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Tardive Dyskinesia

Interventions

DRUG: NBI-98854
DRUG: NBI-98854
DRUG: Placebo

Sponsor

Neurocrine Biosciences